Dr. Diane A. King, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 137 Queen Anne Rd, Bogota, NJ 07603 Phone: 201-488-7855 Fax: 201-488-1636 |
Bogota Family Eye Care Llc Optometrist Medicare: Medicare Enrolled Practice Location: 137 Queen Anne Rd, Bogota, NJ 07603 Phone: 201-488-7855 Fax: 201-488-1636 |
Bogota Vision P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 137 Queen Anne Rd, Bogota, NJ 07603 Phone: 201-488-7855 |
News Archive
Many surgical patients are concerned about the level of pain they will experience. In a new study presented at ANESTHESIOLOGY 2011, researchers from Thomas Jefferson University identified that multimodal analgesia, a combination of pain medication and therapeutic measures to improve pain control, is used less than 25 percent of the time prior to surgery.
Obstetrician/gynecologist offices may be the ideal venue for boosting vaccination rates among women, say researchers at Duke University Medical Center. They reported today on a successful pilot program focused on providing HPV and Tdap vaccines to non-pregnant and post-partum women.
Minimally invasive surgery is increasingly common and effective for operating inside the human abdomen. In these laparoscopic procedures, which use slender, handheld tools inserted into the body of the patient, the skill of the surgeon is the most important factor determining the success of the operation. A team of interdisciplinary researchers led by Rensselaer Polytechnic Institute has won a $2.3 million federal grant to develop a touch-sensitive virtual reality simulator that will standardize how surgeons are trained and certified to perform laparoscopic procedures.
Duke Medicine has agreed to be the title sponsor of the Tobacco Road Marathon to be conducted in Cary, North Carolina on March 21, 2010, the Tobacco Road Marathon Association (TRMA) announced today. The event is now officially named the "Duke Medicine Tobacco Road Marathon."
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
› Verified 8 days ago